Abstract
Background: Percutaneous transluminal renal angioplasty (PTRA) with or without stenting is the gold standard therapy in patients with atherosclerotic renal artery stenosis (aRAS). However, therapeutic success depends on the correct timing of revascularization and the reversibility of the renal damage.
Materials and Methods: We report a case series of patients treated with PTRA for renovascular hypertension and ischemic nephropathy. We measured bilateral renal resistive index (RRI), circulating renal stem cells (RSC), and Neutrophil Gelatinase Associated Lipocalin (NGAL) at baseline and after PTRA at different time points to understand their changes in post-revascularization.
Results: At baseline, the studied patients (n = 5) had different RSC levels. After PTRAs, all patients showed an improvement in blood pressure, while renal function varied differently within the studied subjects. RRI > 0.75 at baseline and the absence of NGAL decrease after PTRAs were associated with post-PTRA renal function worsening, despite an increase of RSC in all patients.
Conclusion: Although limited to a few patients, our observation allowed the exploration of the behaviour of the studied parameters in different degrees of renal ischemia. This revealed different disease models suggesting the importance of further investigations in larger and homogeneous cohorts to confirm that a greater basal RSC percentage, low RRI values before PTRA, and a post-revascularization NGAL reduction could be related to better renal outcomes in aRAS patients.
Keywords: Percutaneous transluminal renal angioplasty, vascular stenting, renal artery stenosis, ischemic nephropathy, renal resistive index, renal staminal cells, NGAL.
[http://dx.doi.org/10.1016/j.semnephrol.2019.10.008] [PMID: 31836041]
[http://dx.doi.org/10.1080/0886022X.2016.1244077] [PMID: 27778533]
[http://dx.doi.org/10.1007/s40620-020-00733-0] [PMID: 32270411]
[http://dx.doi.org/10.1038/ajh.2010.174] [PMID: 20864945]
[http://dx.doi.org/10.1093/qjmed/hcaa295] [PMID: 33098416]
[http://dx.doi.org/10.3390/medicina57090944]
[http://dx.doi.org/10.1681/ASN.2005020195] [PMID: 17093069]
[http://dx.doi.org/10.1016/S0002-9440(10)62276-6] [PMID: 15681837]
[http://dx.doi.org/10.21037/atm-20-6314] [PMID: 33313236]
[http://dx.doi.org/10.3350/cmh.2017.0059] [PMID: 29684978]
[http://dx.doi.org/10.1152/ajprenal.00619.2009] [PMID: 20181666]
[http://dx.doi.org/10.1016/j.cbi.2018.04.018] [PMID: 29704511]
[http://dx.doi.org/10.1126/science.284.5411.143] [PMID: 10102814]
[http://dx.doi.org/10.1681/ASN.2006010089] [PMID: 16885410]
[http://dx.doi.org/10.1681/ASN.2006030275] [PMID: 16988061]
[http://dx.doi.org/10.3109/0886022X.2010.516856] [PMID: 20954976]
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
37
2
